Scotia Responds To Fraud Allegation
A recent article in a UK newspaper, The Telegraph, said UK companyScotia, along with Murdock Healthcare in the USA, had been sent a "pre-penalty notice" by customs officials in St Louis, Missouri.
The article said that the authorities are contemplating assessing a penalty against the companies - jointly and severally - in an amount of just over $18 million, the maximum penalty for "fraud for violation of Title 19 of the US Code, Section 1592."
Commenting on the situation, Scotia said it had received this notification, which refers to alleged mislabeling of some of Scotia's imports into the USA during the period of 1982 to 1992, adding that it has been given the opportunity to demonstrate that the allegations are invalid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze